FindTrial
Sign In

Study on the Value of Peripheral Blood Protein Markers in Precise Diagnosis, Treatment Response, Tumor Recurrence, and Patient Prognosis Prediction of Gliomas

Study on the Value of Peripheral Blood Protein Markers in Precise Diagnosis, Treatment Response, Tumor Recurrence, and Patient Prognosis Prediction of Gliomas

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400091219
Enrollment
Unknown
Registered
2024-10-23
Start date
2024-08-05
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastoma

Interventions

Glioblastoma:None
Non-glioblastoma:None

Sponsors

Zhongnan Hospital of Wuhan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years old; 2. Pathological confirmation of glioma; 3. KPS scores =80

Exclusion criteria

Exclusion criteria: 1. Have suffered from other malignant tumors within the past 5 years; 2. History of severe lung or heart disease; 3. No capacity for civil conduct or limited capacity for civil conduct; 4. The patient has physical or mental illnesses, and the researcher believes that the patient is unable to fully or completely understand the possible complications of this study; 5. Pregnancy (confirmed by serum or urine ß - HCG test) or lactation period; 6. Severe comorbidities, such as uncontrolled hypertension, heart failure, etc

Design outcomes

Primary

MeasureTime frame
serum ß2-Microglobulin;serum GFAP protein;serum YKL-40 protein;serum FABP4 protein;—

Secondary

MeasureTime frame
Fine classification of lymphocytes+TBNK;Non lymphocytic immune cells;—

Countries

China

Contacts

Public ContactZhiqiang Li

Zhongnan Hospital of Wuhan University

lizhiqiang@whu.edu.cn+86 189 0712 3005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026